NCT07599696
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
Recruiting
NAAges 50+InterventionalTreatmentMichigan State UniversityInvestigator-initiated
~100 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Behavioral speech strategies + speech amplification
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Speech intensity
Measured over Day 1
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesMichigan1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Dominant speakers of North American English
Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
Present with changes in their speech/voice
Exclusion
History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
What this trial measures
- Speech intensityDay 1
Decibel sound pressure level (dB SPL) measured from speech audio recordings
- Voice qualityDay 1
Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings
- ArticulationDay 1
Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.